Immune therapies, including CAR-T cells, bispecific antibodies, and antibody-drug conjugates, are revolutionizing the treatment of multiple myeloma. In this review, we discuss clinical trial design considerations relevant to immune therapies. We first examine issues pertinent to specific populations, including elderly, patients with renal impairment, high-risk/extramedullary disease, and prior immune therapies. We then highlight trial designs to optimize the selection of dose and schedule, explore rational combination therapies based on preclinical data, and evaluate the nuances of commonly used endpoints. By exploiting their pharmacokinetic/pharmacodynamic profiles and utilizing novel translational insights, we can optimize the use of immune therapies in multiple myeloma.

Original languageEnglish
Pages (from-to)S35-S45
JournalAmerican Journal of Hematology
Issue numberS2
StatePublished - Mar 2023


Dive into the research topics of 'Trial designs and endpoints for immune therapies in multiple myeloma'. Together they form a unique fingerprint.

Cite this